UBS Asset Management’s real estate and private markets has launched its first U.K. life sciences property strategy, in partnership with Reef Group, with commitments of £400 million (€464 million/$451 million) from first close investors and a gross development value in excess of £2.5 billion (€2.9 billion/$2.8 billion). Deploying a build-to-core approach, the Article 8 strategy seeks development opportunities in the life sciences sector, with a specific focus on good manufacturing practice (GMP) facilities.
To-date, four sites have been secured within the ‘Golden Triangle’ of London, Oxford and Cambridge, with a forecasted gross development value in excess of £2.5 billion (€2.9 billion/$2.8 billion). This includes
